Clinical

Articles

The products may be ineffective, unsafe and could prevent a person from seeking an appropriate diagnosis.

FDA Warns Companies Claiming to Treat Monkeypox

IBSA Pharma is recalling the hypothyroid medication because analyses showed lowered levels of levothyroxine in some lots.

Subpotency Leads to Recall of 27 Lots of Tirosint-SOL


Dosing has been lowered to reduce the risk of liver damage in patients taking Turalio, which is approved to treat patients with a rare tumor that affects the joints.


Daiichi Sankyo Makes Available New Dosing Regimen for Turalio

Epinephrine (L-adrenaline) is a bulk active pharmaceutical ingredient used to manufacture or compound prescription products.

Discolored Product Leads to Recall of Epinephrine Ingredient

Hospira is calling one lot of vancomycin hydrochloride, an antibiotic to treat patients with serious infections caused by methicillin-resistant staphylococci.

Glass Particles in Vial Lead to Vancomycin Recall

Among the most-read product recall stories are those of amoxicillin, metformin, sodium bicarbonate Omnipod 5, and clopidogrel and atenolol.

Best Read Product Recall Stories in 2022

Among the top safety stories this year are Genentech’s warning to Ocrevus label, FDA’s update to GnRH agonists, a study about JAK-inhibitor side effects, FDA’s warning about Prolia in kidney disease and safety issues related to the potential Alzheimer’s disease drug lecanemab.

Best Read Safety Articles of 2022

Testing of the blood pressure medication revealed nitrosamine levels that were above acceptable limits.

Impurities Lead to Lupin Recall of Quinapril 

Lilly’s first-in-class medicine that activates both the GLP-1 and GIP receptors, Mounjaro, is the latest to be included on the FDA’s drug shortages list because of high demand.

Major Diabetes Medications in Short Supply

Lecanemab is an investigational anti-amyloid beta antibody to treat mild cognitive impairment due to Alzheimer’s disease. It is currently under review by the FDA and a decision is expected by Jan. 6. 

Safety & Recalls